Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer

Triple-Negative Breast Cancer Clinical Trial

— BCTOP-T-M01  

Official title:

Precise Treatment for BLIS Subtype of Triple-negative Breast Cancer in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05806060
• Other study ID #: FUSCC-TNBC-BLIS
• Status: Recruiting
• Phase: Phase 3
• Start date: April 25, 2023
• Est. completion date: February 28, 2026

Study information

• Verified date: February 2024
• Source: Fudan University
• Contact: Zhimin Shao
• Phone: 86-021-64175590
• Email: zhimingshao[@]yahoo.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is being conducted to evaluate VEGFR BP102 with nab-paclitaxe or treatment of physician's choice (TPC) versus nab-paclitaxe or TPC in patients for basal-like immune suppressed (BLIS) subtype of triple-negative breast cancer (TNBC) in the first-line teatment of unresectable locally advanced or metastatic TNBC.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 192
• Est. completion date: February 28, 2026
• Est. primary completion date: August 31, 2025
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• ECOG Performance Status of 0-1
• Expected lifetime of not less than three months
• Metastatic or locally advanced, histologically documented TNBC (absence of HER2, ER, and PR expression) with BLIS subtype
• Cancer stage: recurrent or metastatic breast cancer; Local recurrence be confirmed by the researchers could not be radical resection
• Patients had received no previous chemotherapy or targeted therapy for metastatic triple-negative breast cancer
• At least one measurable or non-measurable lesion according to Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1), which didn't receive radiation therapy
• The functions of major organs are basically normal
• For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures as outlined for each specific treatment arm
• Have the cognitive ability to understand the protocol and be willing to participate and to be followed up

Exclusion Criteria:

• Symptomatic, untreated, or actively progressing CNS metastases
• Significant cardiovascular disease
• Adverse reactions of Grade =1 that are still continuing due to previous treatments. Exceptions are those of hair loss or which researchers take it as exception
• Major surgery was performed within 3 weeks of the first course of trial treatment (except for minor outpatient surgery, such as placement of vascular access)
• Pregnancy or breastfeeding, or intention of becoming pregnant during the study
• Other malignancies within 5 years, excluding cured cervical carcinoma in situ, skin basal cell carcinoma, or skin squamous cell carcinoma
• Inability to swallow, chronic diarrhea and intestinal obstruction, there are multiple factors that affect the use and absorption of drugs
• Presence of third-space fluid accumulation that cannot be controlled by drainage or other methods (such as excessive pleural fluid and ascites)
• Participated in clinical trials of other antitumor drugs within 4 weeks before first taking the investigational drug
• Long-term unhealing wound or incomplete healing of fracture
• Patients with known active HBV or HCV infection or hepatitis B DNA=500, or chronic phase with abnormal liver function
• Allergic constitution, or known allergic history of the drug components of this trial; Or allergic to other monoclonal antibodies
• Patients with a history of gastrointestinal bleeding or a clear tendency to gastrointestinal bleeding within the past 6 months, such as esophageal varicose veins with bleeding risk, locally active ulcer lesions, stool occult blood = (++), were not allowed to enter the group; If there is occult blood in the stool (+), gastroscopy is required
• Abdominal fistula, gastrointestinal perforation or abdominal abscess occurred within 28 days before participating in this trial
• Urine protein =2+ and 24h urine protein quantitative > 1.0 g
• Patients suffering from hypertension and unable to reach the normal range after antihypertensive drug treatment (systolic blood pressure >140mmHg, diastolic blood pressure >90mmHg)

Related Conditions & MeSH terms

• Breast Neoplasms
• Triple Negative Breast Neoplasms
• Triple-Negative Breast Cancer

Intervention

Drug:
• VEGFR and nab-paclitaxel, with maintenance of VEGFR and capecitabine
VEGFR bevacizumab 10mg/kg d1,15 ivgtt + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine with bevacizumab maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks and bevacizumab 10mg/kg d1,15 ivgtt every 4 weeks.
• nab-paclitaxel, with maintenance of capecitabine
Nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle. Capecitabine maintenance if intolerable toxicity was observed with no progression. Capecitabine maintenance 1000mg/m2 po bid d1-d14 every 3 weeks.
• Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1
TPC
• VEGFR and TPC
VEGFR bevacizumab and TPC

Locations

Country	Name	City	State
China	Breast cancer institute of Fudan University Cancer Hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PFS	time to progressive disease (according to RECIST1.1)	Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the end of study (approximately 1.5 years)
Secondary	ORR	The proportion of participants whose best outcome is complete remission or partial remission (according to RECIST1.1)	max 6 months
Secondary	DoR	Duration of Overall Response.The date of the first assessed PR/CR (according to RECIST 1.1) to the date of the first assessed tumor progression (according to RECIST 1.1) or death from any cause.	max 6 months
Secondary	DCR	The percentage of subjects with CR+PR+SD and last more than 4 weeks in all of the participants with measurable lesions.	max 6 months
Secondary	OS	Time to death due to any cause	approximately 3 years